Advertisement

Picture EBD Group Bio-Europe Spring 2023 Basel 650x150px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from the Benelux countries Belgium, Luxembourg and The Netherlands or involving organisations from these countries.

Total search results: 1672 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
DeuterOncology–Andrew Lloyd Associates: public relations, 202301 service existent by ALA 2023-01-19
DeuterOncology–Investsud: investment, 202301 financing round Series A toatlling €5.65m incl new investor Investsud Tech 2023-01-19
DeuterOncology–Newton Biocapital: investment, 202301 financing round Series A toatlling €5.65m incl existing investor Newton Biocapital 2023-01-19
DeuterOncology–Noshaq: investment, 202301 financing round Series A toatlling €5.65m incl new investor Noshaq 2023-01-19
DeuterOncology–SEVERAL: investment, 202301 financing round Series A €5.65m with Newton Biocapital + Noshaq + Investsud Tech 2023-01-19
Verogen–Qiagen: investment, 202301c full acquisition of Verogen for $150m in cash 2023-01-09
Hummingbird Bioscience–Synaffix: ADC technology, 202301– license to GlycoConnect + HydraSpace + toxSYN technoligies up to $150m plus royalties 2023-01-04
Affibody–EU (govt): credit, 202212– venture debt loan facility €20m from EIB supported by InvestEU programme 2022-12-22
Numares–EU (govt): credit, 202212– quasi-equity venture debt financing up to €20m from EIB 2022-12-20
Numares–SEVERAL: investment, 202212 financing round €20m from existing investors 2022-12-20
S-Biomedic–Beiersdorf: investment, 202212 acquisition €na of majority share in S-Biomedic NV by Beiersdorf AG 2022-12-16
Minervax–EU (govt): credit, 202212 loan facility €50m from EIB 2022-12-15
ExeVir Bio–EU (govt): credit, 202212– venture debt financing €25m from EIB for develoment of nanobody Covid-19 therapy 2022-12-14
Storm Therapeutics–Merck (DE): investment, 202212 financing round Series B totalling $30m incl existing + co-lead investor M Ventures 2022-12-14
Storm Therapeutics–SEVERAL: investment, 202212 financing round Series B $30m led by M Ventures + Pfizer Ventures + Taiho Ventures + CIC 2022-12-14
MyCellHub–SEVERAL: investment, 202212 financing round €2m with Gemma Frisius Fund + Noshaq + The Factory Fund + LRM 2022-12-08
Neogene Therapeutics–AstraZeneca: investment, 202211–202301 acquisition $200m upfront + $120 milestones on cash/debt free basis 2022-11-29
Biomemory–eureKARE: investment, 202211 seed financing round totalling €5m incl co-lead investor eureKARE 2022-11-28
Biomemory–France (govt): investment, 202211 seed financing round totalling €5m incl co-lead investor French Tech Seed Fund 2022-11-28
Biomemory–SEVERAL: investment, 202211 seed financing round €5m led by eureKARE + French Tech Seed Fund 2022-11-28
Hemispherian–Meneldor: investment, 202211 financing round Series A1 first tranche totalling NOK30m ($2.9m) incl existing + lead investor Meneldor 2022-11-24
Hemispherian–SEVERAL: investment, 202211 financing round Series A1 first tranche of NOK30m ($2.9m) led by Meneldor 2022-11-24
Catalym–BioGeneration Ventures: investment, 202211 financing round Series C totalling €50m incl existing + co-investor BGV 2022-11-22
Catalym–Forbion: investment, 202211 financing round Series C totalling €50m incl existing + co-investor Forbion 2022-11-22
Catalym–Germany (govt): investment, 202211 financing round Series C totalling €50m incl existing + co-investor Coparion 2022-11-22
Catalym–SEVERAL: investment, 202211 financing round Series C €50m led by Brandon Capital + Jeito Capital 2022-11-22
Catalym–Vesalius Biocapital: investment, 202211 financing round Series C totalling €50m incl existing + co-investor Vesalius Biocapital III 2022-11-22
Cradle Bio–Index Ventures: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Index Ventures 2022-11-17
Cradle Bio–Kindred Capital: investment, 202211 seed financing round totalling €5.5m incl co-lead investor Kindred Capital 2022-11-17
Cradle Bio–PERSON: investment, 202211 seed financing round totalling €5.5m incl angel investor Emily LeProust 2022-11-17
Cradle Bio–PERSON: investment, 202211 seed financing round totalling €5.5m incl angel investor Feike Sijbesma 2022-11-17
Cradle Bio–PERSON: investment, 202211 seed financing round totalling €5.5m incl angel investor Sylvain Gariel 2022-11-17
Cradle Bio–SEVERAL: investment, 202211 emerges from stealth with €5.5m seed financing round led by Index Ventures + Kindred Capital 2022-11-17
FundaMental Pharma–SEVERAL: investment, 202211 seed financing round €10m led by BGV + Thuja Capital 2022-11-17
Enzyre–SEVERAL: investment, 202211 financing round Series A €12m (incl Dutch Govt Innovation Credit) led by Oost NL 2022-11-02
Resolve Biosciences–SEVERAL: investment, 202210 financing round Series B $71m led by Patient Square Capital 2022-10-24
VIB–Resolve Biosciences: Molecular Cartography technology, 202210 supply to VIB existent as one of first customers 2022-10-24
Enhanc3D Genomics–Bioqube Ventures: investment, 202210 financing round Series A totalling £10m incl existing + co-investor Bioqube Ventures 2022-10-20
Enhanc3D Genomics–SEVERAL: investment, 202210 financing round Series A £10m led by BGF + Parkwalk Advisors 2022-10-20
Nucleome Therapeutics–Merck (DE): investment, 202210 financing round Series A totalling £37.5m incl new + lead investor M Ventures 2022-10-19
Nucleome Therapeutics–SEVERAL: investment, 202210 financing round Series A £37.5m led by M Ventures 2022-10-19
Orionis Biosciences–SEVERAL: investment, 202210 financing round $55m with Cormorant AM + Novartis et al 2022-10-19
Univercells–SEVERAL: investment, 202210 financing round Series D 1st closing €44m with SFPI-FPIM + SRIW et al 2022-10-19
Mablink Bioscience–Fournier-Majoie Foundation: investment, 202210 financing round Series A totalling €31m incl existing + co-investor Fondation FM 2022-10-14
Mablink Bioscience–SEVERAL: investment, 202210 financing round Series A €31m led by Sofinnova Partners + Mérieux Equity Partners 2022-10-14
Andera Partners–SEVERAL: investment, 202210 final closing of BioDiscovery 6 fund at €456m 2022-10-10
Immatics–SEVERAL: investment, 202210 underwritten offering $110m with 10.9m ordinary shares at $10.09/share 2022-10-10
Crainio–NLC Ventures: investment, 202210 existent seed investor NLC 2022-10-05
Araris Biotech–SEVERAL: investment, 202210 financing round $24m co-led by 4BIO Capital + Pureos Bioventures 2022-10-04
Sibylla Biotech–SEVERAL: investment, 202210 financing round Series A €23m led by V-Bio Ventures 2022-10-04
Sibylla Biotech–V-Bio Ventures: investment, 202210 financing round Series A totalling €23m incl lead investor V-Bio Ventures 2022-10-04
BioDGraft–NLC Ventures: investment, 202209 existent seed investor NLC 2022-09-27
EFOS (SI)–ECBF: investment, 202209 financing round Series B totalling €10m incl lead investor European Circular Bioeconomy Fund 2022-09-20
EFOS (SI)–SEVERAL: investment, 202209 financing round Series B €10m led by ECBF 2022-09-20
Kuros–Alpha Capital: investment, 202209 capital increase totalling CHF6m incl investor Pegasus Global Opportunity Fund Ltd 2022-09-15
Kuros–Optiverder: investment, 202209 capital increase totalling CHF6m incl investor Optiverder BV 2022-09-15
Kuros–SEVERAL: investment, 202209 capital increase CHF6m via private placement with 3.75m new shares at CHF1.6/share 2022-09-15
Tridek-One–Bioqube Ventures: investment, 202209 2nd financing round totalling €16m incl new + co-investor Bioqube Ventures 2022-09-15
Tridek-One–SEVERAL: investment, 202209 2nd financing round €16m led by Pureos Bioventures 2022-09-15
Standing Ovation–Astanor Ventures: investment, 202209 financing round Series A totalling €12m incl lead investor Astanor Ventures 2022-09-14
Standing Ovation–SEVERAL: investment, 202209 financing round Series A €12m lead by Astanor Ventures 2022-09-14
Sanquin–Gilde Investment: investment, 202208– acquisition of Sanquin Reagents from SHS by GHPE IV ANNOUNCED 2022-08-29
eTheRNA–China Grand Pharma: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor Grand Pharma 2022-08-23
eTheRNA–EQT: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor EQT Life Sciences (formerly LSP) 2022-08-23
eTheRNA–Flanders (govt): investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor PMV 2022-08-23
eTheRNA–Fund+: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor Fund+ 2022-08-23
eTheRNA–Novalis LifeSciences: investment, 202208 financing round Series B2 totalling €39m incl existing + lead investor Novalis LifeSciences LLC 2022-08-23
eTheRNA–Omega Funds: investment, 202208 financing round Series B2 totalling €39m incl existing + co-investor Omega Fund 2022-08-23
eTheRNA–PERSON: investment, 202208 financing round Series B2 totalling €39m incl new + co-investor Kenneth Chien 2022-08-23
eTheRNA–SEVERAL: investment, 202208 financing round Series B2 €39m led by existing investor Novalis LifeSciences LLC 2022-08-23
Genome Diagnostics–Eurobio Scientific: investment, 202208– acquisition 100% of GenDx for €135m in cash (net of adjusted cash) 2022-08-17
B Medical Systems–Azenta: investment, 202208–202210 acquisition $410m upfront + $50m milestones 100% of B Medical from Navis Capital 2022-08-08
F2G Ltd–Forbion: investment, 202208 financing round totalling $70m inc new + co-lead investor Forbion 2022-08-04
F2G Ltd–Novo Group: investment, 202208 financing round totalling $70m inc existing + co-investor Novo Holdings 2022-08-04
F2G Ltd–SEVERAL: investment, 202208 financing round $70m co-led by new investors Forbion + Sofinnova Partners 2022-08-04
Haermonics–SEVERAL: investment, 202208 financing round Series C €4.3m led by BOM + Demcon + Stepping Stone/NLC 2022-08-02
SHS Capital–EU (govt): investment, 202207 first closing totalling over €220m of SHS VI fund incl investor EIF 2022-07-18
SHS Capital–SEVERAL: investment, 202207 first closing at over €220m of SHS VI fund with EIF + Realdania + Helsana HealthInvest + LBBW et al. 2022-07-18
Agomab Therapeutics–Asabys Partners: investment, 202207 financing round Series B extension totalling $40.5m incl new + co-investor Asabys Partners 2022-07-13
Agomab Therapeutics–OTHER: investment, 202207 financing round Series B extension totalling $40.5m incl existing-investors 2022-07-13
Agomab Therapeutics–Pfizer: investment, 202207 financing round Series B extension totalling $40.5m incl new + lead investor Pfizer Breakthrough GI 2022-07-13
Agomab Therapeutics–SEVERAL: investment, 202207 financing round Series B extension $40.5m led by Pfizer bringing total Series B to $114m 2022-07-13
Agomab Therapeutics–Walleye Capital: investment, 202207 financing round Series B extension totalling $40.5m incl new + co-investor Walleye Capital 2022-07-13
Cergentis–Solvias: investment, 202207 acquisition €na of Cergentis by Solvias 2022-07-12
Biosyntia–ECBF: investment, 202207 financing round Series B totalling €11.5m incl new + lead investor ECBF 2022-07-07
Biosyntia–SEVERAL: investment, 202207 financing round Series B €11.5m led by new investor ECBF 2022-07-07
Phytolon–DSM: investment, 202207 financing round Series A totalling $14.5m incl new + lead investor DSM Venturing 2022-07-07
Phytolon–SEVERAL: investment, 202207 financing round Series A $14.5m led by DSM Venturing 2022-07-07
Menarini–NewAmsterdam Pharma: obicetrapib, 202206– license excl €115m upfront + €27.5m funding + €863m milestones for cardiovascular in Europe 2022-06-28
Verve Capital Partners–SEVERAL: investment, 202206 1st CHF45m closing of Verve Venture Fund I 2022-06-24
Abound Bio–Galapagos: investment, 202206 acquisition $14m in cash of AboundBio by Galapagos 2022-06-21
Carma Fund–EU (govt): investment, 202206 first closing totalling €47m of Carma Fund I incl investor EIF 2022-06-21
Carma Fund–SEVERAL: investment, 202206 first closing €47m of Carma Fund I with target size of €60m 2022-06-21
CellPoint–Galapagos: investment, 202206 acquisition in cash €125m upfront + €100m milestones of CellPoint by Galapagos 2022-06-21
JnJ–Evotec: drug discovery services, 202206– collab discover novel mode of action drugs using TargetAlloMod platforms for Janssen Pharmaceutica 2022-06-14
ImCheck Therapeutics–EQT: investment, 202206 financing round Series C totalling €80m incl existing + co-investor EQT Life Sciences 2022-06-13
ImCheck Therapeutics–Gimv: investment, 202206 financing round Series C totalling €80m incl existing + co-investor Gimv 2022-06-13
ImCheck Therapeutics–SEVERAL: investment, 202206 financing round Series C €80m co-led by new investors Earlybird + Andera Partners 2022-06-13
ModuVision–Knauer: investment, 202206 acquisition of ModuVision by Knauer 2022-06-13
Forbion–SEVERAL: investment, 202206 first close €470m of Forbion Growth Opportunities Fund II with target size of €600m hard cap 2022-06-09
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17  next pagenext page



Advertisement

Picture [iito] No Tracking 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Join Cluster HealthCapital Berlin Brandenburg 650x300px

» top